Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2

• Published in: Clinical lung cancer Vol. 24; no. 4; pp. 376 - 380
• Main Authors: Tsutani, Yasuhiro, Goldman, Jonathan W., Dacic, Sanja, Yatabe, Yasushi, Majem, Margarita, Huang, Xiangning, Chen, Allen, van der Gronde, Toon, He, Jie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2023
• Subjects: Adjuvant; Antineoplastic Agents - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Early-stage; Humans; Lung Neoplasms - drug therapy; Placebos; Protein Kinase Inhibitors - therapeutic use; Randomized Controlled Trials as Topic; Resectable; Targeted therapy; Tyrosine kinase inhibitor; Resectable; Adjuvant; Early-stage; Tyrosine kinase inhibitor; Targeted therapy

Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M resistance mutations, with demonstrated efficacy in EGFR mutation-positive (EGFRm) non–small c...